Management Strategies for Pediatric Glucocorticoid-Induced Osteoporosis

Overview

Glucocorticoid therapy in children can cause significant osteoporosis and fractures, particularly vertebral fractures that often go undetected without routine imaging. Early identification and timely intervention, primarily with intravenous bisphosphonates, are critical to managing pediatric glucocorticoid-induced osteoporosis (pGIO), although some cases may require novel anabolic treatments.

Background

Glucocorticoids are widely used to treat various pediatric conditions but pose a risk of skeletal morbidity due to their osteotoxic effects. Pediatric glucocorticoid-induced osteoporosis (pGIO) arises from a combination of disease-related bone fragility and glucocorticoid therapy. Vertebral fractures are a hallmark of pGIO and often occur early during treatment, frequently without symptoms. Growth-mediated vertebral body reshaping offers potential for recovery, influencing therapeutic decisions.

Data Highlights

The Canadian STOPP Consortium conducted a 6-year multicenter observational study involving over 400 glucocorticoid-treated children. Key findings included that vertebral fractures align with peak glucocorticoid exposure, are often asymptomatic, and increase the risk of subsequent fractures if untreated. Bone mineral density assessments showed variable results, with some children maintaining normal aBMD despite fracture presence, highlighting the importance of fracture phenotyping over sole reliance on BMD.

Key Findings

• Vertebral fractures are a clinical signature of pediatric glucocorticoid-induced osteoporosis and often occur early in the treatment course.
• Many vertebral fractures are asymptomatic, necessitating routine spine imaging for detection.
• Untreated vertebral fractures increase the risk of future fractures and may progress to vertebral collapse.
• Growth-mediated vertebral body reshaping can restore vertebral dimensions and may reduce the need for osteoporosis therapy in some children.
• Intravenous bisphosphonates are the first-line treatment but may not fully prevent osteoporosis progression in all cases.
• Prevention of first fractures and exploration of anabolic agents represent future directions in managing high-risk pediatric patients.

Clinical Implications

Clinicians should prioritize early and routine spine imaging to detect vertebral fractures in children receiving glucocorticoids, even in the absence of symptoms. Timely initiation of intravenous bisphosphonate therapy is recommended to mitigate fracture progression, while monitoring for potential growth-mediated vertebral reshaping to guide treatment duration. Awareness of cases with attenuated bisphosphonate response underscores the need for individualized management and future research into anabolic therapies.

Conclusion

Pediatric glucocorticoid-induced osteoporosis requires vigilant fracture surveillance and early intervention to optimize bone health outcomes. While bisphosphonates remain the cornerstone of treatment, ongoing research into prevention strategies and anabolic agents is essential to address unmet clinical needs.

References

1. STOPP Consortium Studies (2015-2021) -- Natural History and Management of Pediatric Glucocorticoid-Induced Osteoporosis
2. Greulich and Pyle (1959) -- Radiographic Atlas of Skeletal Development of the Hand and Wrist